Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Structure and Assembly

In Vitro Assembly Properties of Human Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain

Stephen Campbell, Alan Rein
Stephen Campbell
ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Rein
ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.73.3.2270-2279.1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Schematic diagrams of proteins expressed in E. coli and purified proteins. (A) Schematic diagram of HIV-1 Gag and Gag Δp6 used for in vitro assembly. (B) Coomassie blue-stained SDS-polyacrylamide gel of purified proteins. Lanes: 1 and 2, 10 and 100 μg of purified HIV-1 Gag Δp6, respectively; 3, HIV-1 Gag purified in the same manner as Gag Δp6; 4 and 5, anti-p6 antibody affinity purification of HIV-1 Gag; 4, flow-through (FT) from the affinity column; 5, affinity-purified HIV-1 Gag (eluted with p6 peptide). Arrows indicate the protein band referred to in each lane. PC, purified on a phosphocellulose cation-exchange column.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Negatively stained EM images of Gag Δp6 and Gag particles assembled in vitro. (A) Gag Δp6 particles assembled with yeast tRNA; (B) Gag Δp6 particles assembled with an in vitro transcript of HIV-1 packaging sequence (∼1 kb); (C) Gag particles assembled at 4°C with E. coli rRNA; (D) Gag Δp6 particles assembled with MS2 bacteriophage RNA (∼3.5 kb); arrows indicate tails protruding from particles. All panels were negatively stained with 2% uranyl acetate. Scale bars = 50 nm.

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Precipitation of HIV-1 Gag Δp6 with poly(dTG) oligonucleotides (Oligo) of different lengths. HIV-1 Gag Δp6 (100 μg at 5 mg/ml in a solution containing 20 mM Tris [pH 7.5], 0.5 M NaCl, 0.5% NP-40, and 10 mM DTT) was mixed with no oligonucleotide (lanes 1 to 3) or with a 5-base (lanes 4 to 6), 10-base (lanes 7 to 9), or 15-base (lanes 10 to 12) TG oligonucleotide or the 24-base arbitrary oligonucleotide referred to in the text (lanes 13 to 15). The reaction mixtures were then diluted fivefold in pH 8.0 buffer without NaCl (final conditions, 100 μg [at 1 mg/ml] of protein, pH 8.0, 0.1 M NaCl, 0.5% NP-40, 10 mM DTT, 4 μg of oligonucleotide) and incubated for 2 h at room temperature. The precipitates were pelleted by centrifugation in a microcentrifuge for 1 h. Equal portions of the total (T), pellet (P), and supernatant (S) fractions were analyzed by SDS-PAGE and Coomassie blue staining.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Precipitation of HIV-1 Gag Δp6 with oligonucleotides of different lengths, sequences, and oligonucleotide/protein ratios. Assembly reactions with oligonucleotides of different lengths (10, 15, 20, 25, or 30 nt long) and at different oligonucleotide/protein ratios (0, 1, 2, 4, 8, or 16% [wt/wt]) were performed and the products analyzed as described in the legend to Fig. 3. The percentage of protein in each pellet fraction was quantitated by densitometry. (A) Poly(dA) oligonucleotides; (B) poly(dTG) oligonucleotides.

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Cross-linking of HIV-1 Gag Δp6 with oligonucleotides (Oligo) of different lengths. The total reaction mixtures from the experiment of Fig. 3 were cross-linked with increasing amounts (0, 0.5, 1, and 2 mM) of DMS prior to SDS-PAGE and Coomassie blue staining. Lanes: 1 to 4, no oligonucleotide (0); 5 to 8, 5-base poly(dTG); 9 to 12, 10-base poly(dTG); 14 to 17, 15-base poly(dTG); 18 to 21, arbitrary 24-base oligonucleotide referred to in the text. The sizes of the molecular mass markers (M; lane 13) are indicated on the left (in kilodaltons). The positions of the Gag Δp6 cross-linking products are indicated on the right.

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Precipitation of HIV-1 Gag Δp6 with RNA is reversible with RNase A or NaCl treatment. Lanes: 1 to 3, in vitro assembly reactions with HIV-1 Gag Δp6 and no oligonucleotide (0); 4 to 6, yeast tRNA, 4%; 7 to 9, E. coli rRNA, 4%; lanes 10 to 12, bacteriophage MS2, RNA 4%; 13 to 15, poly(dT-dG) 30 DNA, 4% oligonucleotide. T, total; P, pellet; S, supernatant. (A) Assembly reactions in 0.1 M NaCl; (B) assembly reactions from panel A to which NaCl was added to 0.5 M NaCl for 20 min prior to sedimentation; (C) assembly reactions from panel A to which RNase A was added (at 0.1 mg/ml) for 20 min prior to sedimentation.

  • Fig. 7.
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Cross-linking of NaCl-treated HIV-1 Gag Δp6–TG 15 assemblies. Assembly reactions using TG 15, at a oligodeoxynucleotide/protein ratio of 4% (wt/wt), were cross-linked with increasing amounts (0, 0.5, 1, and 2 mM) of DMS prior to SDS-PAGE and Coomassie blue staining. All reaction mixtures were assembled and cross-linked for the same amount of time. Lanes: 1 to 4, no oligonucleotide (Oligo) (0), in 0.5 M NaCl; 5 to 8, TG 15, in 0.1 M NaCl; 9 to 12, TG 15 assembly reaction (in 0.1 M NaCl) to which NaCl was added to 0.5 M for 20 min prior to cross-linking. The sizes of the molecular mass markers (lane 13) are indicated on the left (in kilodaltons). The positions of the Gag Δp6 cross-linking products are indicated on the right.

PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Assembly Properties of Human Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain
Stephen Campbell, Alan Rein
Journal of Virology Mar 1999, 73 (3) 2270-2279; DOI: 10.1128/JVI.73.3.2270-2279.1999

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Assembly Properties of Human Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Assembly Properties of Human Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain
Stephen Campbell, Alan Rein
Journal of Virology Mar 1999, 73 (3) 2270-2279; DOI: 10.1128/JVI.73.3.2270-2279.1999
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Gene Products, gag
HIV-1
virus assembly

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514